

**ASX Announcement**

**20 December 2024**

## **Appendix 3Y – Change of Director’s Interest Notice Late Lodgment**

During a periodic internal review and reconciliation of equity a discrepancy was discovered in the Directors’ interests and disclosures.

To minimize the likelihood of such discrepancies occurring in the future, the Company has requested the share registry implement additional compliance monitoring measures. The Company and the Directors are aware of their obligations under the Corporations Act and ASX Listing Rules 3.19A and 3.19B to provide the necessary information to meet its disclosure requirements.

Please find attached Appendix 3Y – Change of Director’s Interest Notice for Mr. Doug Cubbin.

Yours sincerely

Christian Dal Cin  
Company Secretary

For personal use only

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/9/2001. Amended 01/01/11

<b>Name of Entity:</b>	Oncosil Medical Limited (ASX: OSL)
<b>ABN:</b>	89 113 824 141

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director:</b>	Douglas Cubbin
<b>Date of Last Notice:</b>	20 December 2023

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or Indirect Interest</b>	Direct and Indirect		
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	Related party		
<b>Date of change</b>	13 December 2024		
<b>No. of securities held prior to change</b>		<b>Shares</b>	<b>Options</b>
	Direct	-	5,000,000
	Indirect	-	-
	<b>Total</b>	<b>-</b>	<b>5,000,000</b>
<b>Class</b>	Ordinary shares and options		
<b>Number acquired</b> See below "Nature of change".		<b>Shares</b>	<b>Options</b>
	Direct	-	-
	Indirect	25,000,000	32,500,000
	<b>Total</b>	<b>25,000,000</b>	<b>32,500,000</b>
<b>Number disposed</b>		<b>Shares</b>	<b>Options</b>
	Direct	-	-
	Indirect	-	-
	<b>Total</b>	<b>-</b>	<b>-</b>

+ See chapter 19 for defined terms.

For personal use only

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	May 2024 \$0.005 per share with attaching options. Dec 2024 \$0.01 per share with attaching option.												
<b>No. of securities held after change</b>	<table border="1"> <thead> <tr> <th></th> <th>Shares</th> <th>Options</th> </tr> </thead> <tbody> <tr> <td>Direct</td> <td>-</td> <td>5,000,000</td> </tr> <tr> <td>Indirect</td> <td>25,000,000</td> <td>32,500,000</td> </tr> <tr> <td><b>Total</b></td> <td><b>25,000,000</b></td> <td><b>37,500,000</b></td> </tr> </tbody> </table>		Shares	Options	Direct	-	5,000,000	Indirect	25,000,000	32,500,000	<b>Total</b>	<b>25,000,000</b>	<b>37,500,000</b>
	Shares	Options											
Direct	-	5,000,000											
Indirect	25,000,000	32,500,000											
<b>Total</b>	<b>25,000,000</b>	<b>37,500,000</b>											
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of Placement Equity approved by shareholders at General Meetings held on 15 May 2024 and 11 Dec 2024. <table border="1"> <thead> <tr> <th>Issue Date</th> <th>Shares</th> <th>Options</th> </tr> </thead> <tbody> <tr> <td>20 May 2024</td> <td>15,000,000</td> <td>22,500,000</td> </tr> <tr> <td>13 Dec 2024</td> <td>10,000,000</td> <td>10,000,000</td> </tr> <tr> <td><b>Total</b></td> <td><b>25,000,000</b></td> <td><b>32,500,000</b></td> </tr> </tbody> </table>	Issue Date	Shares	Options	20 May 2024	15,000,000	22,500,000	13 Dec 2024	10,000,000	10,000,000	<b>Total</b>	<b>25,000,000</b>	<b>32,500,000</b>
Issue Date	Shares	Options											
20 May 2024	15,000,000	22,500,000											
13 Dec 2024	10,000,000	10,000,000											
<b>Total</b>	<b>25,000,000</b>	<b>32,500,000</b>											

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	N/A
<b>Interest after change</b>	N/A

+ See chapter 19 for defined terms.

**Part 3 – Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

---

+ See chapter 19 for defined terms.

For personal use only